Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 16Unknown 3Terminated 3Active not recruiting 3Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Melanoma 14Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hematologic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Solid Tumor 1Sarcoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma 1Lymphatic Metastasis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hemangiosarcoma 1Esophageal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

trametinib 2olaparib 1glembatumumab vedotin 1durvalumab 1cediranib 1Vorinostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1CR011-vcMMAE 1Biopsy, Fine-Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Uveal Melanoma × Ipilimumab × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡